Concepedia

Shruta Rege

SR

Statistics

Publications

4

Citations

161

H-Index

4

Active since

2012

Affiliations

Cubist Pharmaceuticals (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Shruta Rege is an author at Cubist Pharmaceuticals (United States) specializing in pharmacotherapy, antibiotics, and patient safety.

Top concepts

Publications per year

2012–2017

4

Publications

4

Randomized Controlled Trial of the Safety and Efficacy of Daptomycin versus Standard-of-Care Therapy for Management of Patients with Osteomyelitis Associated with Prosthetic Devices Undergoing Two-Stage Revision Arthroplasty

Ivor Byren, Shruta Rege, Ed Campanaro et al. · Antimicrobial Agents and Chemotherapy · 2012 · 91 citations · Full text

Surotomycin versus vancomycin for<i>Clostridium difficile</i>infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial

Christine H. Lee, Hernando Patino, Chris Stevens et al. · Journal of Antimicrobial Chemotherapy · 2016 · 44 citations · Full text

Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and Experience

Shruta Rege, John Mohr, Kenneth C. Lamp et al. · International Journal of Antimicrobial Agents · 2013 · 16 citations

, , +5

Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers

Gurudatt Chandorkar, Qiao Zhan, Julie Donovan et al. · BMC Pharmacology and Toxicology · 2017 · 10 citations · Full text

1–4 of 4